Vertex Pharmaceuticals
VRTX · NASDAQ · USD · Healthcare
Kurs
−1,7 % seit 21.9.20261 Monat · Hoch 529,89 $ (−5,3 %) · Tief 484,08 $
Was gerade passiert
Vertex Pharmaceuticals ist seit dem 6-Wochen-Hoch am 8.9.2026 um 6 % gefallen. Wie es weitergeht – Phase und Anzeichen – siehst du mit einem kostenlosen Konto.
Kostenloses Konto · 3 Werte pro TagWie tief ist der Rücksetzer?
- vom 6-Wochen-Hoch−6,2 %
Höchster Tageskurs: 535,00 $ am 8.9.2026 · Bezug der Einschätzung
- vom 3-Monats-Hoch−10,4 %
Höchster Tageskurs in 3 Monaten: 560,25 $ am 3.9.2026
- vom 52-Wochen-Hoch−10,4 %
Höchster Kurs in 52 Wochen: 560,25 $ (Yahoo)
Markieren löst keine Order aus – es hilft dir nur beim Verfolgen.
Katalysatoren
vor 14 Min.- Nachrichten, letzte 10 Tage
- keine aktuellen Nachrichten
- Nächste Zahlen
- 2.11.2026 · in 13 Tagen
- Letzter Bericht
- 3.8.2026 -0.3% vs. Schätzung
Handelsmarken
Warum die Engine so urteilt
Verlauf für diesen Wert
Beobachten und Alarm
Über Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Sitz:
- Boston, United States
- 52-Wochen-Spanne:
- 403,16 $ – 560,25 $
- Website:
- vrtx.com
Signale entstehen automatisch aus Kurs, Volumen und technischen Indikatoren. Sie sind keine Anlageberatung.← Zurück zur Suche
